JLL vs RNA · P/E 23, rev $13.31B vs rev $22.6M
Jones Lang LaSalle Incorporated (JLL) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported JLL revenue for 2026-06-30 was $13.31B. Net income was $373.7M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
JLL currently screens at market cap $12.12B and trailing P/E 23.0. RNA currently screens at market cap $217.5M.
Not investment advice. Open the JLL and RNA stock pages for the full models.
Not investment advice.